THE FACTS

» According to the WHO, panic disorder and PTSD are the top two causes of inability to carry out everyday activities in high-income nations, averaging 45.6 and 31.5 days “out of role,” respectively.

» Panic attacks accompany a range of other chronic conditions (i.e. diabetes, asthma, IBS, CV).

» While many people suffer from panic attacks, only 20% of people who experience panic attacks are diagnosed with panic disorder.

» Historically, treatment options were limited to psychotherapy and medication.

THE COMPANY’S SOLUTION

» Freespira, an IMPACT member, is a prescription digital therapeutic* with 1:1 telehealth training and coaching throughout the 28-day treatment.

» The FDA-cleared system for treating panic disorder, panic attacks and PTSD symptoms addresses dysfunctional breathing arising from carbon dioxide hypersensitivity.

» In partnership with Managed Medicaid health plans, Freespira:

(1) Analyzes claims data for patterns of medical diagnoses and utilization to identify potential candidates for treatment, including previously undiagnosed

(2) Develops co-branded awareness and education materials for patients and providers

(3) Communicates continuously with patients and providers throughout the treatment protocol to ensure strong adherence and clinical outcomes.

WHY IT MATTERS

» Freespira shares engagement, adherence and clinical outcome metrics with payor partners and expands access to treatment for challenging and underserved populations.

» Freespira’s clinical outcomes result in lower utilization of specific healthcare services (e.g., ER usage, which has a spend 4-5x higher in this patient population) driving cost savings.

*Digital therapeutics (DTx) deliver medical interventions directly to patients using evidence-based, clinically tested software with or without custom hardware to treat, manage, and prevent a broad spectrum of diseases and disorders.